Hemispherx BioPharma, Inc (NYSEAMERICAN: HEB) is having an incredibly strong start to the trading session this morning, and for good reason. The comapny announced significant progress in a clinical oncology program.
Read my full report on HEB here!
As you could imagine, the news excited investors, pushing the stock on a run for the top. Today, we’ll talk about:
- The clinical update;
- what we’re seeing from HEB stock as a result; and
- what we’ll be watching for ahead.
HEB Gains On Clinical Update
As mentioned above, Hemispherx Biopharma is having a great start to the trading session this morning after announcing a clinical update. The update came by way of press release early this morning.
In the release, HEB announced significant progress in its Ampligen recurrent ovarian cancer program. The program is currently taking place at the University of Pittsburgh Medical Center (UPMC), under the leadership of Robert Edwards, MD, the principal investigator on the trial.
The company said that the program is being funded in part by an Ovarian Cancer Specialized Program of Research Excellence (SPORE) from the National Institutes of Health (NIH), supporting a Phase 1/2 study of intraperitoneal chemo-immunotherapy in recurrent ovarian cancer.
The data show local immune response during chemo-induced cell dealth as measured by serial assessment of peritoneal fluid cellular phenotypes and chemokine patterns. In a statement, Dr. Edwards, lead investigator on the trial, had the following to offer:
Ampligen has the potential to be clinically significant because a robust killer T-cell population in the tumor microenvironment without attracting Treg cells is important to help optimize checkpoint blockade induced tumor shrinkage.
The above statement was followed up by Thomas K. Equels, CEO at HEB, here’s what he had to offer:
Ovarian cancer is projected to kill 152,000 this year worldwide. Recurrent ovarian cancer is a dire unmet medical need. Working with the University of Pittsburgh, we are able to team up and focus world-class science on developing a meaningful combination therapy with the potential to save the lives of women who may be out of therapeutic options.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that it’s important to follow the news closely. After all, it’s the news that moves the market, and in the case of Hemispherx BioPharma, the news proved to be positive.
After all, these positive results show that the treatment is working in the right direction down the development path. So, it’s not surprising to see that excited investors are pushing the stock on a run for the top.
As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:54), HEB is trading at $0.24 per share after a gain of $0.068 per share or 40.29% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on HEB. in particular, we’re interested in following the story surrounding the company’s continued work to develop the assets in its impressive oncology focused pipeline. Nonetheless, we’ll continue to keep a close eye on the story and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!